Wedbush upgraded Staar Surgical to Outperform from Neutral with a price target of $40, up from $26. The Q1 report brings confidence that Staar is either at or nearing an inflection point for a full China rebound, the analyst tells investors in a research note. Wedbush says it is taking a longer-term view to the Staar Surgical story. It would \"rather be early than late\" as the firm believes the company has the potential to exceed even its bull case scenario in the coming quarters. Further China recovery progress is likely to lead to valuation re-rating and multiple expansion to historical levels, Wedbush contends.
